MedPath

Clomipramine

Generic Name
Clomipramine
Brand Names
Anafranil
Drug Type
Small Molecule
Chemical Formula
C19H23ClN2
CAS Number
303-49-1
Unique Ingredient Identifier
NUV44L116D

Overview

Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H receptors, α-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.

Background

Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H receptors, α-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.

Indication

May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.

Associated Conditions

  • Depression
  • Obsessive Compulsive Disorder (OCD)
  • Panic Disorder

Clinical Trials

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Mizner Bioscience, LLC
86039-114
ORAL
20 mg in 1 1
5/27/2025
Alembic Pharmaceuticals Inc.
62332-409
ORAL
75 mg in 1 1
10/12/2021
TruPharma LLC
52817-281
ORAL
50 mg in 1 1
11/17/2022
Zydus Lifesciences Limited
70771-1013
ORAL
50 mg in 1 1
9/21/2023
Covetrus North America
11695-6952
ORAL
40 mg in 1 1
5/27/2025
Alembic Pharmaceuticals Limited
46708-407
ORAL
25 mg in 1 1
1/27/2023
Lupin Pharmaceuticals, Inc.
68180-493
ORAL
50 mg in 1 1
10/31/2023
MWI/VetOne
13985-975
ORAL
20 mg in 1 1
5/27/2025
SpecGx LLC
0406-9908
ORAL
75 mg in 1 1
11/29/2023
Golden State Medical Supply, Inc.
51407-757
ORAL
25 mg in 1 1
4/25/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
APO-CLOMIPRAMINE TABLET 25 mg
SIN09018P
TABLET, FILM COATED
25 mg
11/28/1996
APO-CLOMIPRAMINE TABLET 10 mg
SIN09058P
TABLET, FILM COATED
10 mg
12/9/1996
DEPRANIL TABLET 25 mg
SIN09611P
TABLET
25 mg
1/26/1998

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Clomipramine Hydrochloride Injection
国药准字H20055612
化学药品
注射剂
7/14/2020
Clomipramine Hydrochloride Injection
国药准字H10910016
化学药品
注射剂
3/22/2021
Clomipramine Hydrochloride Tablets
国药准字H11022409
化学药品
片剂
11/9/2020
Clomipramine Hydrochloride Tablets
国药准字H10920086
化学药品
片剂
7/26/2022
Clomipramine Hydrochloride Tablets
国药准字H10900027
化学药品
片剂(薄膜衣)
6/10/2020
Clomipramine Hydrochloride Tablets
国药准字H31021286
化学药品
片剂(糖衣)
12/23/2019
Clomipramine Hydrochloride Tablets
国药准字H11022404
化学药品
片剂(糖衣)
11/18/2020
Clomipramine Hydrochloride Tablets
国药准字H12020277
化学药品
片剂
3/27/2020
Clomipramine Hydrochloride Tablets
国药准字H32022975
化学药品
片剂
7/14/2020
Clomipramine Hydrochloride Tablets
国药准字H31022082
化学药品
片剂(糖衣)
1/16/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath